Business
Marker Therapeutics Reports First Quarter 2021 Operating and Financial Results
Marker continues to advance Phase 2 AML trial, recently dosing first patient Company closed financing extending cash runway into Q1 2023 Company to host
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"Marker continues to advance Phase 2 AML trial, recently dosing first patient\n Company closed financing extending cash runway into Q1 2023\n Company to host conference call and webcast today at 5:00 p.m. ET\n\n\nHOUSTON, May 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. \n\n \n \n \n \n \n \n\n \n\"We had a productive first quarter supported by our recently completed financing, strengthening our overall cash position and enabling continued growth and expansion of our Multi-TAA pipeline,\" said Peter L. Hoang, President & CEO of Marker Therapeutics. \"In addition, we continue to make strong progress on both the clinical and manufacturing fronts. In March, we dosed the first patient in the safety lead-in portion of our Phase 2 trial in post-transplant acute myeloid leukemia, or AML, and continue to activate clinical sites. In parallel, we continue to optimize the MT-401 cell therapy manufacturing process, which we believe could result in an increase in the number of T cells available for patient administration—among other benefits—as we prepare to operationalize our new in-house cGMP facility in the first half of the year.\"\nPROGRAM UPDATES\nIn March 2021, Marker dosed the first patient in the safety lead-in portion of its Phase 2 trial in AML, which is expected to enroll a total of six patients: three of which will be treated with MT-401 manufactured with a legacy reagent, and the remaining three to be treated with study drug manufactured with a new reagent from an alternate supplier. The clinical operations team has made considerable progress in opening sites to enroll patients for the safety lead-in portion of the AML trial. The Company has also received commitments from additional clinical sites to participate in the Phase 2 AML trial following the safety lead-in phase and anticipates activating a total of approximately 20 sites. Marker continues to streamline and simplify the MT-401 manufacturing process, which could potentially result in a product with a superior T cell phenotype and improved antigen sp...